What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NKX019 is an investigational allogeneic CD19-Directed CAR NK”In the company’s words, NCT06557265 on ClinicalTrials.gov
- Tested for
- Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis, Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia and 8 more
- Main trialPhase 1/2
- “This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.”In the company’s words, NCT06557265 on ClinicalTrials.gov
Other drugs for Lupus Nephritis
- AnifrolumabAstraZeneca · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- IanalumabNovartis · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
Coming up2
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Apr 2027 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | |
| Phase 1/2Recruiting | Oct 2028 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | |
| Phase 1Active, not recruiting | 31 Mar 2025 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026